Insider Transactions in Q1 2024 at Blueprint Medicines Corp (BPMC)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 28
2024
|
Michael Landsittel CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
5,000
-9.56%
|
$475,000
$95.0 P/Share
|
|
Mar 28
2024
|
Michael Landsittel CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+8.73%
|
$180,000
$36.05 P/Share
|
|
Mar 20
2024
|
Jeffrey W. Albers |
SELL
Open market or private sale
|
Direct |
25,073
-2.62%
|
$2,181,351
$87.33 P/Share
|
|
Mar 20
2024
|
Jeffrey W. Albers |
BUY
Exercise of conversion of derivative security
|
Direct |
25,073
+6.02%
|
$200,584
$8.44 P/Share
|
|
Mar 15
2024
|
Michael Landsittel CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
13,734
-4.14%
|
$1,208,592
$88.06 P/Share
|
|
Mar 15
2024
|
Michael Landsittel CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+7.57%
|
$180,000
$36.05 P/Share
|
|
Mar 15
2024
|
Ariel Hurley PRINCIPAL ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
4,549
-8.36%
|
$400,312
$88.19 P/Share
|
|
Mar 15
2024
|
Ariel Hurley PRINCIPAL ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,600
+4.11%
|
$24,000
$15.01 P/Share
|
|
Mar 13
2024
|
Philina Lee CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
8,023
-9.74%
|
$722,070
$90.22 P/Share
|
|
Mar 13
2024
|
Philina Lee CHIEF COMMERCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,747
+2.01%
|
$19,217
$11.91 P/Share
|
|
Mar 07
2024
|
Jeffrey W. Albers |
SELL
Open market or private sale
|
Direct |
11,033
-6.27%
|
$992,970
$90.69 P/Share
|
|
Mar 07
2024
|
Philina Lee CHIEF COMMERCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,934
-6.68%
|
$264,060
$90.69 P/Share
|
|
Mar 07
2024
|
Kate Haviland CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
12,464
-7.52%
|
$1,121,760
$90.69 P/Share
|
|
Mar 07
2024
|
Debra Durso Bumpus CHIEF PEOPLE OFFICER |
SELL
Open market or private sale
|
Direct |
5,093
-8.13%
|
$458,370
$90.69 P/Share
|
|
Mar 07
2024
|
L. Becker Hewes CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,097
-6.27%
|
$278,730
$90.69 P/Share
|
|
Mar 07
2024
|
Fouad Namouni PRESIDENT, R & D |
SELL
Open market or private sale
|
Direct |
4,377
-5.68%
|
$393,930
$90.69 P/Share
|
|
Mar 07
2024
|
Christina Rossi CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
6,070
-8.63%
|
$546,300
$90.69 P/Share
|
|
Mar 07
2024
|
Michael Landsittel CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
5,003
-8.2%
|
$450,270
$90.69 P/Share
|
|
Mar 07
2024
|
Christopher K. Murray CHIEF TECHNICAL OPERATIONS |
SELL
Open market or private sale
|
Direct |
2,521
-6.93%
|
$226,890
$90.69 P/Share
|
|
Mar 07
2024
|
Ariel Hurley PRINCIPAL ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
1,462
-7.57%
|
$131,580
$90.69 P/Share
|
|
Mar 07
2024
|
Tracey L Mc Cain EVP AND CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
5,194
-7.91%
|
$467,460
$90.69 P/Share
|
|
Mar 07
2024
|
Percy H. Carter CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
2,286
-4.52%
|
$205,740
$90.69 P/Share
|
|
Mar 04
2024
|
Christopher K. Murray CHIEF TECHNICAL OPERATIONS |
SELL
Open market or private sale
|
Direct |
621
-1.68%
|
$57,753
$93.65 P/Share
|
|
Mar 01
2024
|
Ariel Hurley PRINCIPAL ACCOUNTING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
5,000
+20.56%
|
-
|
|
Mar 01
2024
|
Tracey L Mc Cain EVP AND CHIEF LEGAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+15.99%
|
-
|
|
Mar 01
2024
|
Philina Lee CHIEF COMMERCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+22.15%
|
-
|
|
Mar 01
2024
|
Christina Rossi CHIEF OPERATING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+17.57%
|
-
|
|
Mar 01
2024
|
Debra Durso Bumpus CHIEF PEOPLE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+16.63%
|
-
|
|
Mar 01
2024
|
Fouad Namouni PRESIDENT, R & D |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+16.29%
|
-
|
|
Mar 01
2024
|
Percy H. Carter CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+19.8%
|
-
|
|
Mar 01
2024
|
Michael Landsittel CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+17.0%
|
-
|
|
Mar 01
2024
|
Kate Haviland CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+19.45%
|
-
|
|
Mar 01
2024
|
L. Becker Hewes CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+20.2%
|
-
|
|
Mar 01
2024
|
Christopher K. Murray CHIEF TECHNICAL OPERATIONS |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+25.26%
|
-
|
|
Feb 28
2024
|
Christopher K. Murray CHIEF TECHNICAL OPERATIONS |
SELL
Open market or private sale
|
Direct |
5,000
-16.95%
|
$500,000
$100.0 P/Share
|
|
Feb 28
2024
|
Christopher K. Murray CHIEF TECHNICAL OPERATIONS |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+14.49%
|
$270,000
$54.13 P/Share
|
|
Jan 25
2024
|
Jeffrey W. Albers |
SELL
Open market or private sale
|
Direct |
25,000
-3.24%
|
$2,050,000
$82.3 P/Share
|
|
Jan 25
2024
|
Jeffrey W. Albers |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+6.01%
|
$200,000
$8.44 P/Share
|